Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement (Q37898560)

25 August 2017

1 reference

title

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement (English)

1 reference

metastatic renal cell carcinoma

25 August 2017

1 reference

1 reference

1

1 reference

25 August 2017

G Tortora

2

0 references

author name string

C Linassier

3

1 reference

25 August 2017

K Papazisis

4

1 reference

25 August 2017

A Awada

5

1 reference

25 August 2017

D Berthold

6

1 reference

25 August 2017

J P Maroto

7

1 reference

25 August 2017

T Powles

8

1 reference

25 August 2017

M De Santis

9

1 reference

25 August 2017

7 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

29

1 reference

25 August 2017

3

1 reference

25 August 2017

1896-1907

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-011-0016-8

25 August 2017

0 references

cites work

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sunitinib and other targeted therapies for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sunitinib rechallenge in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0016-8

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

21 January 2018

1 reference

12 December 2020

Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study

1 reference

12 December 2020

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

1 reference

12 December 2020

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

1 reference

12 December 2020

Axitinib for renal cell carcinoma

1 reference

12 December 2020

10.1007/S12032-011-0016-8

Identifiers

DOI

1 reference

25 August 2017

1 reference